NO20053773L - Parentale peptidformuleringer for behandling av systemisk lupus erytematosus - Google Patents

Parentale peptidformuleringer for behandling av systemisk lupus erytematosus

Info

Publication number
NO20053773L
NO20053773L NO20053773A NO20053773A NO20053773L NO 20053773 L NO20053773 L NO 20053773L NO 20053773 A NO20053773 A NO 20053773A NO 20053773 A NO20053773 A NO 20053773A NO 20053773 L NO20053773 L NO 20053773L
Authority
NO
Norway
Prior art keywords
amino acids
sequence
peptide
composition
systemic lupus
Prior art date
Application number
NO20053773A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053773D0 (no
Inventor
Ety Klinger
Sharon Cohen-Vered
Esmira Naftali
Adrian Gilbert
Vera Weinstein
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of NO20053773D0 publication Critical patent/NO20053773D0/no
Publication of NO20053773L publication Critical patent/NO20053773L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Rehabilitation Therapy (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
NO20053773A 2003-01-14 2005-08-08 Parentale peptidformuleringer for behandling av systemisk lupus erytematosus NO20053773L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43991803P 2003-01-14 2003-01-14
PCT/US2004/000948 WO2004064787A2 (en) 2003-01-14 2004-01-14 Parenteral formulations of peptides for the treatment of systemic lupus erythematosus

Publications (2)

Publication Number Publication Date
NO20053773D0 NO20053773D0 (no) 2005-08-08
NO20053773L true NO20053773L (no) 2005-10-12

Family

ID=32771757

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053773A NO20053773L (no) 2003-01-14 2005-08-08 Parentale peptidformuleringer for behandling av systemisk lupus erytematosus

Country Status (21)

Country Link
US (3) US20050008634A1 (pt)
EP (1) EP1594434B1 (pt)
JP (2) JP4817068B2 (pt)
KR (1) KR20050100617A (pt)
CN (1) CN1774259B (pt)
AU (1) AU2004206842A1 (pt)
BR (1) BRPI0406745A (pt)
CA (1) CA2513320C (pt)
CO (1) CO5640143A2 (pt)
CR (1) CR7938A (pt)
DK (1) DK1594434T3 (pt)
EA (1) EA009123B1 (pt)
EC (1) ECSP055961A (pt)
ES (1) ES2606464T3 (pt)
IL (1) IL169574A (pt)
IS (1) IS7972A (pt)
MX (1) MXPA05007549A (pt)
NO (1) NO20053773L (pt)
NZ (1) NZ541658A (pt)
WO (1) WO2004064787A2 (pt)
ZA (1) ZA200506206B (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
NZ541659A (en) * 2003-01-14 2007-05-31 Teva Pharma Pharmaceutical composition comprising with a pH between 4 and 9 to treat SLE comprising an aqueous carrier, a pharmaceutically acceptable salt of a peptide and a substituted beta-cyclodextrin
US7635773B2 (en) 2008-04-28 2009-12-22 Cydex Pharmaceuticals, Inc. Sulfoalkyl ether cyclodextrin compositions
BRPI0916072A2 (pt) * 2008-11-17 2015-11-10 Genentech Inc "uso de uma formulação, formulação farmacêutica, usos de um anticorpo 2h7 humanizado, método, método para aumentar a biodisponibilidade de um anticorpo e método de diálise in vitro"
HUE058834T2 (hu) 2012-02-15 2022-09-28 Cydex Pharmaceuticals Inc Elõállítási eljárás ciklodextrin-származékokhoz
MX2015000532A (es) * 2012-07-12 2015-05-15 Sanofi Sa Composicion anti-tumoral que comprende el compuesto 1- (6- { [6- (4-fluorofenil) [1,2,4] triazolo [4,3-b] piridazin-3-il] sulfanil} -1,3-benzotiazol-2-il) -3- (2-morfolin-4-iletil) urea.
WO2014066274A1 (en) 2012-10-22 2014-05-01 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
WO2014193611A1 (en) * 2013-05-29 2014-12-04 Oklahoma Medical Research Foundation Bright/arid3a function/expression as a marker for systemic lupus erythematosus severity and intensity
WO2015013669A1 (en) 2013-07-26 2015-01-29 The Regents Of The University Of California Mps peptides and use thereof
US10314889B2 (en) * 2013-12-20 2019-06-11 The Regents Of The University Of California Suppression of allergic lung inflammation and hyperreactivity
HUE063851T2 (hu) 2014-08-22 2024-02-28 Cydex Pharmaceuticals Inc Frakcionált alkilezett ciklodextrin készítmények és eljárás ezek elõállítására és alkalmazására
US10525137B2 (en) 2015-12-30 2020-01-07 Genentech, Inc. Formulations with reduced degradation of polysorbate
JOP20170017B1 (ar) 2016-01-25 2021-08-17 Amgen Res Munich Gmbh تركيب صيدلي يتضمن تركيبات جسم مضاد ثنائي الاختصاص
US11167005B2 (en) 2017-01-05 2021-11-09 Yeda Research And Development Co. Ltd. Peptides for treating Sjogren's syndrome
US11105555B2 (en) 2017-04-04 2021-08-31 Nitto Denko Corporation Method for manufacturing freeze-dried body and manufacturing device for same
US10975121B2 (en) 2017-06-24 2021-04-13 Cytogel Pharma, Llc Analgesic mu-opioid receptor binding peptide pharmaceutical formulations and uses thereof
CN111683654A (zh) * 2017-11-30 2020-09-18 细胞凝胶制药有限责任公司 新型镇痛药物制剂及其用途
CN115038723A (zh) 2019-11-18 2022-09-09 锡德克斯药物公司 烷基化环糊精组合物及其制备和使用方法
US12698348B2 (en) 2020-09-24 2026-08-04 Cydex Pharmaceuticals, Inc. Alkylated cyclodextrin compositions and processes for preparing and using the same
CN112143707A (zh) * 2020-09-29 2020-12-29 广东先康达生物科技有限公司 一种治疗自身免疫细胞的免疫细胞及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60184098A (ja) * 1984-03-02 1985-09-19 Suntory Ltd 新規なペプチド及びこれを有効成分とする利尿剤
US6407079B1 (en) * 1985-07-03 2002-06-18 Janssen Pharmaceutica N.V. Pharmaceutical compositions containing drugs which are instable or sparingly soluble in water and methods for their preparation
US5997856A (en) * 1988-10-05 1999-12-07 Chiron Corporation Method and compositions for solubilization and stabilization of polypeptides, especially proteins
US5126249A (en) * 1989-05-09 1992-06-30 Eli Lilly And Company Enzymatic removal of a protein amino-terminal sequence
KR0166088B1 (ko) * 1990-01-23 1999-01-15 . 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도
US5376645A (en) * 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
GB9200247D0 (en) * 1992-01-07 1992-02-26 Erba Carlo Spa Pharmaceutical compositions containing polymer derivative-bound anthracycline glycosides and a method for their preparation
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
US6613536B1 (en) * 1995-03-28 2003-09-02 Yeda Research And Development Co. Ltd. Synthetic peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
IL113159A0 (en) * 1995-03-28 1995-06-29 Yeda Res & Dev Synthetic peptides and pharmaceutical compositions comprising them
IL120503A0 (en) * 1997-03-20 1997-07-13 Hadasit Med Res Service Peptides for the treatment of systemic lupus erythematosis and pharmaceutical compositions containing them
US20020054872A1 (en) * 1997-03-20 2002-05-09 Yaakov Naparstek Peptides for the treatment of systemic lupus erythematosus and methods of treating systemic lupus erythematosus
SE9802938D0 (sv) * 1998-09-01 1998-09-01 Astra Ab Improved stability for injection solutions
IL141647A0 (en) * 2001-02-26 2002-03-10 Yeda Res & Dev Synthetic human peptides and pharmaceutical compositions comprising them for the treatment of systemic lupus erythematosus
NZ541659A (en) * 2003-01-14 2007-05-31 Teva Pharma Pharmaceutical composition comprising with a pH between 4 and 9 to treat SLE comprising an aqueous carrier, a pharmaceutically acceptable salt of a peptide and a substituted beta-cyclodextrin
DK1594434T3 (da) * 2003-01-14 2017-01-02 Yeda Res & Dev Company Ltd At The Weizmann Inst Of Science Parenterale formuleringer af peptide til behandling af systemisk lupus erythematosus
US7018891B2 (en) * 2003-12-16 2006-03-28 International Business Machines Corporation Ultra-thin Si channel CMOS with improved series resistance

Also Published As

Publication number Publication date
IL169574A (en) 2015-08-31
EA009123B1 (ru) 2007-10-26
EA200501131A1 (ru) 2006-04-28
BRPI0406745A (pt) 2005-12-20
ZA200506206B (en) 2006-12-27
JP4817068B2 (ja) 2011-11-16
WO2004064787A3 (en) 2005-12-15
MXPA05007549A (es) 2006-05-19
CO5640143A2 (es) 2006-05-31
EP1594434B1 (en) 2016-09-07
AU2004206842A1 (en) 2004-08-05
IS7972A (is) 2006-07-15
EP1594434A4 (en) 2008-09-10
IL169574A0 (en) 2007-07-04
WO2004064787A2 (en) 2004-08-05
US20130023485A1 (en) 2013-01-24
NO20053773D0 (no) 2005-08-08
NZ541658A (en) 2008-04-30
JP2006517540A (ja) 2006-07-27
CA2513320A1 (en) 2004-08-05
EP1594434A2 (en) 2005-11-16
CR7938A (es) 2006-05-31
US20050008634A1 (en) 2005-01-13
ECSP055961A (es) 2006-04-19
CA2513320C (en) 2018-03-27
KR20050100617A (ko) 2005-10-19
DK1594434T3 (da) 2017-01-02
US20090169559A1 (en) 2009-07-02
CN1774259B (zh) 2011-12-28
JP2011173888A (ja) 2011-09-08
CN1774259A (zh) 2006-05-17
ES2606464T3 (es) 2017-03-24

Similar Documents

Publication Publication Date Title
WO2004064787A3 (en) Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
ES2566830T3 (es) Péptido capaz de extender la semivida de péptido de interés en plasma
CN101815724B (zh) 用于将轭合至其的试剂递送至组织的抑肽酶样多肽
Chorev The partial retro–inverso modification: A road traveled together
ES2404940T3 (es) Reactivos de peptoide específicos para prión
JP2022513798A (ja) トランスフェリン受容体標的ペプチド
US9534040B2 (en) Antiviral agent against animal viruses
NO20045021L (no) Immunologiske metoder og preparater for behandling av Alzheimers sykdom
EA200400289A1 (ru) Производные аминоизоксазола, активные в качестве ингибиторов киназы
CN109891245A (zh) 自身免疫疾病的诊断、预防和/或治疗
EP1578361A4 (en) IMMUNOGENOUS AND CORRESPONDING ANTIBODIES SPECIFIC FOR COMMON HIGH-MOLECULAR AGGREGATION INTERMEDIATE PRODUCTS OF AMYLOIDS FROM PROTEINS OF DIFFERENT SEQUENCE
NO20063026L (no) Antistoffer
US20230330238A1 (en) Chimeric conjugates for degradation of viral and host proteins and methods of use
JP2006506942A5 (pt)
BR0015875A (pt) Anticorpos igm humano com a capacidade de induzir remielinização, e usos diagnósticos e terapêutico dos mesmos, particularmente no sistema nervoso central
DK1417222T3 (da) Isolerede polypeptider baseret på den neutraliserende epitop af p17-proteinet fra HIV egnet til vacciner samt neutraliserende anti-p17-antistoffer, der specifikt genkender nævnte neutraliserende epitop
NO331277B1 (no) Farmasoytisk sammensetning omfattende polypetid/nukleinsyre for behandling av retinale degenererende sykdommer, vektor, isolert polypeptid, renset antistoff og anvendelse av polypeptid, nukleinsyre og antistoff, samt fremgangsmater og kit
WO2017192594A1 (en) Binding moieties for biofilm remediation
EA200501129A1 (ru) Парентеральные композиции пептида для лечения системной красной волчанки
JP2001103993A (ja) 環状ペプチド及びセリンプロテアーゼ阻害剤
CN118401542A (zh) 抗病毒的装钉结构的SARS-CoV-2肽-胆固醇缀合物及其用途
WO2005002500A2 (en) Inhibitors of coronavirus
Silva et al. Synthetic angiotensin II peptide derivatives confer protection against cerebral and severe non-cerebral malaria in murine models
RU2005126236A (ru) Фьюжн-белок для подавления цервикального рака
RU2007115411A (ru) Пептиды hsp60 и их apl-производные и фармацевтические композиции

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application